Dr. Braslavsky of Thomas Jefferson University Hospital in Philadelphia has no relevant relationships to disclose.)
Dr. Sperling of Thomas Jefferson University in Philadelphia received research contracts from SK Life Science, UCB, Takeda, Neurelis, Engage Therapeutics, Medtronic, Eisai, Cavion, Xenon, and Cerevel; a consulting fee from Medtronic; and speaker honorariums from Eisai and UCB.)
Dr. Stern, Director of the Epilepsy Clinical Program at the University of California in Los Angeles, received honorariums from Eisai, Greenwich, SK Life Sciences, and UCB Pharma as an advisor and from Eisai, Greenwich, LivaNova, Neurelis, and UCB Pharma as a lecturer.)
About 80% of persons with epilepsy inhabit low and middle income countries (LMICs). Studies have shown that up to 70% of newly diagnosed children and adults with epilepsy are successfully treated with antiepileptic drugs. In lower income regions, up to 75% of people with epilepsy may not receive the treatment they need. The treatment gap in these regions needs to be narrowed to decrease morbidity and mortality due to epilepsy.
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.